دورية أكاديمية
أعرض في EDS

In vivo antitumor effect of endostatin-loaded chitosan nanoparticles combined with paclitaxel on Lewis lung carcinoma.

التفاصيل البيبلوغرافية
العنوان: In vivo antitumor effect of endostatin-loaded chitosan nanoparticles combined with paclitaxel on Lewis lung carcinoma.
المؤلفون: Xie F; a Department of Oncology , Affiliated Hospital of Southwest Medical University , Luzhou , Sichuan , China., Ding RL; b Experiment and Training Center , Sichuan College of Traditional Chinese Medicine , Mianyang , Sichuan , China., He WF; a Department of Oncology , Affiliated Hospital of Southwest Medical University , Luzhou , Sichuan , China., Liu ZJ; a Department of Oncology , Affiliated Hospital of Southwest Medical University , Luzhou , Sichuan , China., Fu SZ; a Department of Oncology , Affiliated Hospital of Southwest Medical University , Luzhou , Sichuan , China., Wu JB; a Department of Oncology , Affiliated Hospital of Southwest Medical University , Luzhou , Sichuan , China., Yang LL; a Department of Oncology , Affiliated Hospital of Southwest Medical University , Luzhou , Sichuan , China., Lin S; a Department of Oncology , Affiliated Hospital of Southwest Medical University , Luzhou , Sichuan , China., Wen QL; a Department of Oncology , Affiliated Hospital of Southwest Medical University , Luzhou , Sichuan , China.
المصدر: Drug delivery [Drug Deliv] 2017 Nov; Vol. 24 (1), pp. 1410-1418.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Taylor & Francis Country of Publication: England NLM ID: 9417471 Publication Model: Print Cited Medium: Internet ISSN: 1521-0464 (Electronic) Linking ISSN: 10717544 NLM ISO Abbreviation: Drug Deliv Subsets: MEDLINE
أسماء مطبوعة: Publication: 2015->: Abingdon, Oxford : Taylor & Francis
Original Publication: Orlando, FL : Academic Press, c1993-
مواضيع طبية MeSH: Carcinoma, Lewis Lung* , Nanoparticles*, Animals ; Cell Line, Tumor ; Chitosan ; Endostatins ; Mice ; Mice, Inbred C57BL ; Paclitaxel ; Vascular Endothelial Growth Factor A
مستخلص: The purpose of this study was to prepare endostatin-loaded chitosan nanoparticles (ES-NPs) and evaluate their antitumor effect when combined with paclitaxel (PTX) on Lewis lung carcinoma (LLC) mouse xenografts. ES-NPs were prepared by ionic cross-linking. Characterization of the ES-NPs included size distribution, drug-loading efficiency (DL), and encapsulation efficiency (EE). An in vitro release test was also used to determine the release behavior of the ES-NPs. A subcutaneous LC xenograft model of C57BL/6J mice was established. The mice were randomly divided into six groups: control (0.9% NaCl), ES, PTX, ES-NPs, ES + PTX, and ES-NPs + PTX. The tumor volume was dynamically measured for the duration of the experiment. Immunohistochemistry was performed to determine the Ki-67 and microvascular density (MVD) in each group. Serum vascular endothelial growth factor (VEGF) and ES levels were determined by enzyme-linked immunosorbent assay (ELISA). ES-NPs were successfully synthesized and had suitable size distribution and high EE. The NPs were homogenously spherical and exhibited an ideal release profile in vitro. In vivo, tumor growth was significantly inhibited in the ES-NPs + PTX group. The tumor inhibitory rate was significantly higher in the ES-NPs + PTX group than in the other groups (p < .05). The results of the immunohistochemical assay and ELISA confirmed that ES-NPs combined with PTX had a strong antiangiogenic effect. ES-NPs can overcome the shortcomings of free ES, such as short retention time in circulation, which enhances the antitumor effect of ES. The antitumor effect was more pronounced when treatment included PTX and ES-loaded NPs.
References: Cell. 1997 Jan 24;88(2):277-85. (PMID: 9008168)
Pharm Res. 2009 Aug;26(8):1918-30. (PMID: 19507009)
Adv Drug Deliv Rev. 2016 Apr 1;99(Pt A):70-84. (PMID: 26639578)
Macromol Biosci. 2004 Apr 19;4(4):383-98. (PMID: 15468229)
Adv Drug Deliv Rev. 2010 Jan 31;62(1):59-82. (PMID: 19925837)
World J Surg Oncol. 2012 Aug 24;10:170. (PMID: 22917490)
Exp Mol Pathol. 2009 Jun;86(3):215-23. (PMID: 19186176)
Asian Pac J Cancer Prev. 2015;16(9):4013-8. (PMID: 25987078)
J Clin Oncol. 2013 Mar 10;31(8):1039-49. (PMID: 23401433)
ACS Appl Mater Interfaces. 2014 Jul 23;6(14):11413-23. (PMID: 24977925)
Int J Nanomedicine. 2011;6:1535-41. (PMID: 21845043)
Microvasc Res. 2007 Sep-Nov;74(2-3):72-84. (PMID: 17560615)
Annu Rev Chem Biomol Eng. 2011;2:281-98. (PMID: 22432620)
Nat Rev Clin Oncol. 2010 Nov;7(11):653-64. (PMID: 20838415)
Clin Cancer Res. 2012 Mar 15;18(6):1641-54. (PMID: 22275507)
CA Cancer J Clin. 2017 Jan;67(1):7-30. (PMID: 28055103)
J Biol Chem. 2002 Aug 2;277(31):27872-9. (PMID: 12029087)
Med Oncol. 2013 Dec;30(4):698. (PMID: 23982676)
Asian Pac J Trop Med. 2015 Aug;8(8):664-7. (PMID: 26321522)
Drug Deliv. 2017 Nov;24(1):300-308. (PMID: 28165807)
Drug Discov Today. 2003 Mar 15;8(6):259-66. (PMID: 12623240)
Drug Dev Ind Pharm. 2017 Aug;43(8):1304-1313. (PMID: 28402175)
Dig Liver Dis. 2009 Feb;41(2):116-22. (PMID: 19038587)
Biochem Biophys Res Commun. 2007 Sep 14;361(1):79-84. (PMID: 17644065)
Biotechnol Adv. 2015 Nov 1;33(6 Pt 3):1355-69. (PMID: 25687276)
J Thorac Oncol. 2011 Jun;6(6):1104-9. (PMID: 21532504)
Nat Commun. 2016 Aug 19;7:12528. (PMID: 27538380)
Mol Cancer Res. 2006 Feb;4(2):61-70. (PMID: 16513837)
Clin Cancer Res. 2010 Jun 1;16(11):2989-2998. (PMID: 20406842)
J Control Release. 2012 Feb 10;157(3):383-90. (PMID: 21864592)
J Nucl Med. 2008 Jun;49 Suppl 2:24S-42S. (PMID: 18523064)
Int J Pharm. 2013 Oct 15;455(1-2):219-28. (PMID: 23886649)
BMC Cancer. 2016 Apr 11;16:266. (PMID: 27067521)
Cancer Res. 2003 Dec 15;63(24):8890-8. (PMID: 14695206)
Anal Chem. 2014 Jul 15;86(14):7041-8. (PMID: 24896224)
CA Cancer J Clin. 2015 Mar;65(2):87-108. (PMID: 25651787)
J Oncol Pract. 2012 Jan;8(1):63-6. (PMID: 22548014)
Int J Nanomedicine. 2008;3(4):487-96. (PMID: 19337417)
Zhongguo Fei Ai Za Zhi. 2005 Aug 20;8(4):283-90. (PMID: 21108883)
Biomaterials. 1995 Nov;16(16):1211-6. (PMID: 8589189)
Pharm Res. 1997 Oct;14(10):1431-6. (PMID: 9358557)
Nature. 2005 Dec 15;438(7070):967-74. (PMID: 16355214)
فهرسة مساهمة: Keywords: Endostatin; chitosan; lung cancer; nanoparticles; paclitaxel
المشرفين على المادة: 0 (Endostatins)
0 (Vascular Endothelial Growth Factor A)
9012-76-4 (Chitosan)
P88XT4IS4D (Paclitaxel)
تواريخ الأحداث: Date Created: 20170922 Date Completed: 20171214 Latest Revision: 20240530
رمز التحديث: 20240530
مُعرف محوري في PubMed: PMC8241112
DOI: 10.1080/10717544.2017.1378938
PMID: 28933203
قاعدة البيانات: MEDLINE
الوصف
تدمد:1521-0464
DOI:10.1080/10717544.2017.1378938